Immunosuppressants - Russia

Russia

In Russia, the Immunosuppressants market is forecasted to achieve a revenue of US$239.80m by the year 2024.
The market is anticipated to exhibit a compound annual growth rate (CAGR 2024-2029) of 14.61%, leading to a market volume of US$474.30m by 2029.
When compared globally, United States will generate the highest revenue in this market, reaching US$35,470.00m in 2024.
Russia's growing demand for immunosuppressants is driven by an increasing prevalence of autoimmune diseases and organ transplantation.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for immunosuppressants in Russia has been on a steady rise in recent years.

Customer preferences: Patients with autoimmune disorders, organ transplant recipients, and those with inflammatory bowel disease are the primary consumers of immunosuppressants in Russia. The preference for generic drugs over branded ones is high in the country, as they are more affordable.

Trends in the market: The Russian government has implemented measures to increase domestic production of drugs, including immunosuppressants, leading to a surge in local production. This has resulted in a price drop for the drugs, making them more accessible to patients. The use of biosimilars is also on the rise, as they are more cost-effective and have similar efficacy to the original drugs.

Local special circumstances: The prevalence of autoimmune disorders and inflammatory bowel disease is higher in Russia than in other European countries, which has led to an increase in demand for immunosuppressants. The country also has a high rate of organ transplant procedures, with kidney transplants being the most common. This has contributed to the growth of the immunosuppressants market in the country.

Underlying macroeconomic factors: The Russian pharmaceutical market has been growing steadily, with an increasing number of international pharmaceutical companies investing in the country. The government has also been implementing measures to improve the healthcare system and increase access to medication for patients. The country's aging population and the rise in chronic diseases have also contributed to the growth of the immunosuppressants market. However, the economic sanctions imposed on Russia by Western countries have had a negative impact on the pharmaceutical industry, leading to a shortage of some drugs in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.